Division of Surgical Oncology, Department of Surgery, James Graham Brown Cancer, University of Louisville School of Medicine, 315 East Broadway, Louisville, KY 40202, USA.
Surg Clin North Am. 2010 Aug;90(4):839-52. doi: 10.1016/j.suc.2010.04.012.
Colorectal adenocarcinoma remains the third most common cause of cancer death in the United States, with an estimated 146,000 new cases and 50,000 deaths annually. Survival is stage dependent, and the presence of liver metastases is a primary determinant in patient survival. Approximately 25% of new cases will present with synchronous colorectal liver metastases (CLM), and up to one-half will develop CLM during the course of their disease. The importance of safe and effective therapies for CLM cannot be overstated. Safe and appropriately aggressive multimodality therapy for CLM can provide most patients with liver-dominant colorectal metastases with extended survival and an improved quality of life.
结直肠癌仍然是美国第三大常见的癌症死因，每年估计有 14.6 万例新发病例和 5 万例死亡。生存率取决于分期，肝转移的存在是患者生存的主要决定因素。大约 25%的新发病例将出现结直肠肝转移（CLM），多达一半的病例在疾病过程中会发展为 CLM。安全有效的 CLM 治疗方法的重要性怎么强调都不为过。对于 CLM，安全且适当积极的多模式治疗可以为大多数肝转移为主的结直肠癌患者提供延长的生存时间和提高生活质量。
